Neuroinflammation in Alzheimer's disease

The Lancet Neurology

Volumn 14, Issue 4, 2015, Pages 388-405

  Heneka, Michael T ^a,b   Carson, Monica J ^c   Khoury, Joseph El ^d   Landreth, Gary E ^e   Brosseron, Frederic ^b   Feinstein, Douglas L ^f   Jacobs, Andreas H ^g,h   Wyss Coray, Tony ^i,j   Vitorica, Javier ^k   Ransohoff, Richard M ^l   Herrup, Karl ^m   Frautschy, Sally A ⁿ   Finsen, Bente ^o   Brown, Guy C ^p   Verkhratsky, Alexei ^q,r,s   Yamanaka, Koji ^t   Koistinaho, Jari ^u   Latz, Eicke ^v,w   Halle, Annett ^x   Petzold, Gabor C ^a,b   Town, Terrence ^y   Morgan, Dave ^z   Shinohara, Mari L ^aa   Perry, V Hugh ^ab   Holmes, Clive ^ac,ad   Bazan, Nicolas G ^ae   Brooks, David J ^af   Hunot, Stéphane ^ag   Joseph, Bertrand ^ah   Deigendesch, Nikolaus ^ai   Garaschuk, Olga ^aj   Boddeke, Erik ^ak   Dinarello, Charles A ^al   Breitner, John C ^am   Cole, Greg M ⁿ   Golenbock, Douglas T ^w   Kummer, Markus P ^a   more..

^a UNIVERSITY HOSPITAL BONN   (Germany)

^b GERMAN CENTER FOR NEURODEGENERATIVE DISEASES DZNE   (Germany)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

^e CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^g Johanniter Krankenhaus   (Germany)

^h UNIVERSITY OF MÜNSTER   (Germany)

ⁱ STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^j VA PALO ALTO HEALTH CARE SYSTEM   (United States)

^k HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^l LERNER RESEARCH INSTITUTE   (United States)

^m HONG KONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Hong Kong)

ⁿ UNIVERSITY OF CALIFORNIA   (United States)

^o UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^p UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^q UNIVERSITY OF MANCHESTER   (United Kingdom)

^r BASQUE FOUNDATION FOR SCIENCE   (Spain)

^s UNIVERSITY OF THE BASQUE COUNTRY UPV EHU   (Spain)

^t NAGOYA UNIVERSITY   (Japan)

^u UNIVERSITY OF EASTERN FINLAND   (Finland)

^v UNIVERSITY OF BONN   (Germany)

^w UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^x CENTER OF ADVANCED EUROPEAN STUDIES AND RESEARCH CAESAR   (Germany)

^y UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^z UNIVERSITY OF SOUTH FLORIDA   (United States)

^aa DUKE UNIVERSITY MEDICAL CENTER   (United States)

^ab SOUTHAMPTON GENERAL HOSPITAL   (United Kingdom)

^ac UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^ad MOORGREEN HOSPITAL   (United Kingdom)

^ae LOUISIANA STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^af HAMMERSMITH HOSPITAL   (United Kingdom)

^ag CNRS   (France)

^ah KAROLINSKA INSTITUTE   (Sweden)

^ai MAX PLANCK INSTITUTE FOR INFECTION BIOLOGY   (Germany)

^aj UNIVERSITY OF TÜBINGEN   (Germany)

^ak UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^al UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^am DOUGLAS MENTAL HEALTH UNIVERSITY INSTITUTE   (Canada)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFLAMMATORY AGENT; BAPINEUZUMAB; BIOLOGICAL MARKER; CASPASE; CHEMOKINE; CYTOKINE; NEUROPROTECTIN D1; NITRIC OXIDE; PATTERN RECOGNITION RECEPTOR; PROSTANOID; PROTEIN; REACTIVE OXYGEN METABOLITE; UNCLASSIFIED DRUG; AUTACOID; NONSTEROID ANTIINFLAMMATORY AGENT; NOOTROPIC AGENT;

ALZHEIMER DISEASE; ASTROCYTOSIS; BRAIN DEGENERATION; COMPLEMENT SYSTEM; DISEASE COURSE; DISEASE SEVERITY; GENETIC ANALYSIS; GENETIC RISK; GLIOSIS; HUMAN; IMMUNIZATION; IMMUNOMODULATION; IMMUNOTHERAPY; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATION; INNATE IMMUNITY; LASER MICROSCOPY; LOCUS CERULEUS; MACROGLIA; MICROGLIA; MILD COGNITIVE IMPAIRMENT; MOLECULAR IMAGING; MOUSE MODEL; NERVOUS SYSTEM INFLAMMATION; NEUROMONITORING; NONHUMAN; OBESITY; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FOLDING; REVIEW; RISK FACTOR; TRAUMATIC BRAIN INJURY; UPREGULATION; ANIMAL; ASTROCYTE; BLOOD; BRAIN INJURY; CEREBROSPINAL FLUID; CLINICAL TRIAL (TOPIC); COMPLICATION; DISEASE MODEL; GENETICS; IMMUNOLOGY; METABOLISM; PATHOLOGY; PHAGOCYTOSIS; SEVERITY OF ILLNESS INDEX;

ALZHEIMER DISEASE; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASTROCYTES; BIOLOGICAL MARKERS; BRAIN INJURIES; CLINICAL TRIALS AS TOPIC; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; HUMANS; IMMUNITY, INNATE; IMMUNIZATION; INFLAMMATION; INFLAMMATION MEDIATORS; LOCUS COERULEUS; MICROGLIA; NOOTROPIC AGENTS; OBESITY; PHAGOCYTOSIS; PROTEIN FOLDING; RISK FACTORS; SEVERITY OF ILLNESS INDEX;

EID: 84926370173     PISSN: 14744422     EISSN: 14744465     Source Type: Journal    
DOI: 10.1016/S1474-4422(15)70016-5     Document Type: Review

References (232)

1. Zhang B, Gaiteri C, Bodea L-G, et al. Integrated systems approach identifies genetic nodes and networks in late-onset Alzheimer's disease. Cell 2013, 153:707-720.
2. Guerreiro R, Wojtas A, Bras J, et al. TREM2 variants in Alzheimer's disease. N Engl J Med 2013, 368:117-127. the Alzheimer Genetic Analysis Group.
3. Bradshaw EM, Chibnik LB, Keenan BT, et al. CD33 Alzheimer's disease locus: altered monocyte function and amyloid biology. Nat Neurosci 2013, 16:848-850. the Alzheimer Disease Neuroimaging Initiative.
4. Griciuc A, Serrano-Pozo A, Parrado AR, et al. Alzheimer's disease risk gene CD33 inhibits microglial uptake of amyloid beta. Neuron 2013, 78:631-643.
5. Kettenmann H, Hanisch U-K, Noda M, Verkhratsky A Physiology of microglia. Physiol Rev 2011, 91:461-553.
6. Ji K, Akgul G, Wollmuth LP, Tsirka SE Microglia actively regulate the number of functional synapses. PLoS One 2013, 8:e56293.
7. Parkhurst CN, Yang G, Ninan I, et al. Microglia promote learning-dependent synapse formation through brain-derived neurotrophic factor. Cell 2013, 155:1596-1609.
8. Bamberger ME, Harris ME, McDonald DR, Husemann J, Landreth GE A cell surface receptor complex for fibrillar beta-amyloid mediates microglial activation. J Neurosci 2003, 23:2665-2674.
9. Paresce DM, Ghosh RN, Maxfield FR Microglial cells internalize aggregates of the Alzheimer's disease amyloid beta-protein via a scavenger receptor. Neuron 1996, 17:553-565.
10. Stewart CR, Stuart LM, Wilkinson K, et al. CD36 ligands promote sterile inflammation through assembly of a Toll-like receptor 4 and 6 heterodimer. Nat Immunol 2010, 11:155-161.
11. Liu Y, Walter S, Stagi M, et al. LPS receptor (CD14): a receptor for phagocytosis of Alzheimer's amyloid peptide. Brain 2005, 128:1778-1789.
12. Querfurth HW, LaFerla FM Alzheimer's disease. N Engl J Med 2010, 362:329-344.
13. Kummer MP, Heneka MT Truncated and modified amyloid-beta species. Alzheimers Res Ther 2014, 6:28.
14. El Khoury JB, Moore KJ, Means TK, et al. CD36 mediates the innate host response to beta-amyloid. J Exp Med 2003, 197:1657-1666.
15. Sheedy FJ, Grebe A, Rayner KJ, et al. CD36 coordinates NLRP3 inflammasome activation by facilitating intracellular nucleation of soluble ligands into particulate ligands in sterile inflammation. Nat Immunol 2013, 14:812-820.
16. Lee CYD, Landreth GE The role of microglia in amyloid clearance from the AD brain. J Neural Transm 2010, 117:949-960.
17. Mawuenyega KG, Sigurdson W, Ovod V, et al. Decreased clearance of CNS β-amyloid in Alzheimer's disease. Science 2010, 330:1774.
18. Hickman SE, Allison EK, El Khoury J Microglial dysfunction and defective beta-amyloid clearance pathways in aging Alzheimer's disease mice. J Neurosci 2008, 28:8354-8360.
19. Frank S, Burbach GJ, Bonin M, et al. TREM2 is upregulated in amyloid plaque-associated microglia in aged APP23 transgenic mice. Glia 2008, 56:1438-1447.
20. Hickman SE, Kingery ND, Ohsumi TK, et al. The microglial sensome revealed by direct RNA sequencing. Nat Neurosci 2013, 16:1896-1905.
21. Hsieh CL, Koike M, Spusta SC, et al. A role for TREM2 ligands in the phagocytosis of apoptotic neuronal cells by microglia. J Neurochem 2009, 109:1144-1156.
22. Sierra-Filardi E, Puig-Kröger A, Blanco FJ, et al. Activin A skews macrophage polarization by promoting a proinflammatory phenotype and inhibiting the acquisition of anti-inflammatory macrophage markers. Blood 2011, 117:5092-5101.
23. Colton CA, Mott RT, Sharpe H, Xu Q, Van Nostrand WE, Vitek MP Expression profiles for macrophage alternative activation genes in AD and in mouse models of AD. J Neuroinflammation 2006, 3:27.
24. Mantovani A, Sica A, Sozzani S, Allavena P, Vecchi A, Locati M The chemokine system in diverse forms of macrophage activation and polarization. Trends Immunol 2004, 25:677-686.
25. Mantovani A, Sozzani S, Locati M, Allavena P, Sica A Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol 2002, 23:549-555.
26. Koenigsknecht-Talboo J, Landreth GE Microglial phagocytosis induced by fibrillar beta-amyloid and IgGs are differentially regulated by proinflammatory cytokines. J Neurosci 2005, 25:8240-8249.
27. Goerdt S, Orfanos CE Other functions, other genes: alternative activation of antigen-presenting cells. Immunity 1999, 10:137-142.
28. Zelcer N, Khanlou N, Clare R, et al. Attenuation of neuroinflammation and Alzheimer's disease pathology by liver x receptors. Proc Natl Acad Sci USA 2007, 104:10601-10606.
29. Colton C, Wilcock DM Assessing activation states in microglia. CNS Neurol Disord Drug Targets 2010, 9:174-191.
30. Town T, Laouar Y, Pittenger C, et al. Blocking TGF-beta-Smad2/3 innate immune signaling mitigates Alzheimer-like pathology. Nat Med 2008, 14:681-687.
31. Xue J, Schmidt SV, Sander J, et al. Transcriptome-based network analysis reveals a spectrum model of human macrophage activation. Immunity 2014, 40:274-288.
32. Perry VH, Teeling J Microglia and macrophages of the central nervous system: the contribution of microglia priming and systemic inflammation to chronic neurodegeneration. Semin Immunopathol 2013, 35:601-612.
33. Orre M, Kamphuis W, Dooves S, et al. Reactive glia show increased immunoproteasome activity in Alzheimer's disease. Brain 2013, 136:1415-1431.
34. Simard AR, Soulet D, Gowing G, Julien J-P, Rivest S Bone marrow-derived microglia play a critical role in restricting senile plaque formation in Alzheimer's disease. Neuron 2006, 49:489-502.
35. El Khoury J, Toft M, Hickman SE, et al. Ccr2 deficiency impairs microglial accumulation and accelerates progression of Alzheimer-like disease. Nat Med 2007, 13:432-438.
36. Mildner A, Schlevogt B, Kierdorf K, et al. Distinct and non-redundant roles of microglia and myeloid subsets in mouse models of Alzheimer's disease. J Neurosci 2011, 31:11159-11171.
37. Hawkes CA, McLaurin J Selective targeting of perivascular macrophages for clearance of beta-amyloid in cerebral amyloid angiopathy. Proc Natl Acad Sci USA 2009, 106:1261-1266.
38. Ginhoux F, Greter M, Leboeuf M, et al. Fate mapping analysis reveals that adult microglia derive from primitive macrophages. Science 2010, 330:841-845.
39. Grathwohl SA, Kälin RE, Bolmont T, et al. Formation and maintenance of Alzheimer's disease beta-amyloid plaques in the absence of microglia. Nat Neurosci 2009, 12:1361-1363.
40. Streit WJ, Braak H, Xue Q-S, Bechmann I Dystrophic (senescent) rather than activated microglial cells are associated with tau pathology and likely precede neurodegeneration in Alzheimer's disease. Acta Neuropathol 2009, 118:475-485.
41. Krabbe G, Halle A, Matyash V, et al. Functional impairment of microglia coincides with beta-amyloid deposition in mice with Alzheimer-like pathology. PLoS One 2013, 8:e60921.
42. Lucin KM, O'Brien CE, Bieri G, et al. Microglial beclin 1 regulates retromer trafficking and phagocytosis and is impaired in Alzheimer's disease. Neuron 2013, 79:873-886.
43. Yamanaka M, Ishikawa T, Griep A, Axt D, Kummer MP, Heneka MT PPARγ/RXRα-induced and CD36-mediated microglial amyloid-β phagocytosis results in cognitive improvement in amyloid precursor protein/presenilin 1 mice. J Neurosci 2012, 32:17321-17331.
44. Cramer PE, Cirrito JR, Wesson DW, et al. ApoE-directed therapeutics rapidly clear β-amyloid and reverse deficits in AD mouse models. Science 2012, 335:1503-1506.
45. Fitz NF, Cronican AA, Lefterov I, Koldamova R Comment on "ApoE-directed therapeutics rapidly clear β-amyloid and reverse deficits in AD mouse models". Science 2013, 340:924. 92c.
46. Price AR, Xu G, Siemienski ZB, et al. Comment on "ApoE-directed therapeutics rapidly clear β-amyloid and reverse deficits in AD mouse models". Science 2013, 340:924. 92d.
47. Tesseur I, Lo AC, Roberfroid A, et al. Comment on "ApoE-directed therapeutics rapidly clear β-amyloid and reverse deficits in AD mouse 'models". Science 2013, 340:924. 92e.
48. Veeraraghavalu K, Zhang C, Miller S, et al. Comment on "ApoE-directed therapeutics rapidly clear β-amyloid and reverse deficits in AD mouse models". Science 2013, 340:924. 92f.
49. Sofroniew MV Molecular dissection of reactive astrogliosis and glial scar formation. Trends Neurosci 2009, 32:638-647.
50. Sofroniew MV, Vinters HV Astrocytes: biology and pathology. Acta Neuropathol 2010, 119:7-35.
51. Medeiros R, LaFerla FM Astrocytes: conductors of the Alzheimer disease neuroinflammatory symphony. Exp Neurol 2013, 239:133-138.
52. Olabarria M, Noristani HN, Verkhratsky A, Rodríguez JJ Concomitant astroglial atrophy and astrogliosis in a triple transgenic animal model of Alzheimer's disease. Glia 2010, 58:831-838.
53. Kummer MP, Hammerschmidt T, Martinez A, et al. Ear2 deletion causes early memory and learning deficits in APP/PS1 mice. J Neurosci 2014, 34:8845-8854.
54. Olabarria M, Noristani HN, Verkhratsky A, Rodríguez JJ Age-dependent decrease in glutamine synthetase expression in the hippocampal astroglia of the triple transgenic Alzheimer's disease mouse model: mechanism for deficient glutamatergic transmission?. Mol Neurodegener 2011, 6:55.
55. Yeh C-Y, Vadhwana B, Verkhratsky A, Rodríguez JJ Early astrocytic atrophy in the entorhinal cortex of a triple transgenic animal model of Alzheimer's disease. ASN Neuro 2011, 3:271-279.
56. Kulijewicz-Nawrot M, Verkhratsky A, Chvátal A, Syková E, Rodríguez JJ Astrocytic cytoskeletal atrophy in the medial prefrontal cortex of a triple transgenic mouse model of Alzheimer's disease. J Anat 2012, 221:252-262.
57. Beauquis J, Pavía P, Pomilio C, et al. Environmental enrichment prevents astroglial pathological changes in the hippocampus of APP transgenic mice, model of Alzheimer's disease. Exp Neurol 2013, 239:28-37.
58. Furman JL, Sama DM, Gant JC, et al. Targeting astrocytes ameliorates neurologic changes in a mouse model of Alzheimer's disease. J Neurosci 2012, 32:16129-16140.
59. Wyss-Coray T, Loike JD, Brionne TC, et al. Adult mouse astrocytes degrade amyloid-beta in vitro and in situ. Nat Med 2003, 9:453-457.
60. Koistinaho M, Lin S, Wu X, et al. Apolipoprotein E promotes astrocyte colocalization and degradation of deposited amyloid-beta peptides. Nat Med 2004, 10:719-726.
61. Jiang Q, Lee CYD, Mandrekar S, et al. ApoE promotes the proteolytic degradation of Aβ. Neuron 2008, 58:681-693.
62. Terwel D, Steffensen KR, Verghese PB, et al. Critical role of astroglial apolipoprotein E and liver X receptor-α expression for microglial Aβ phagocytosis. J Neurosci 2011, 31:7049-7059.
63. Saido T, Leissring MA Proteolytic degradation of amyloid β-protein. Cold Spring Harb Perspect Med 2012, 2:a006379.
64. Pihlaja R, Koistinaho J, Kauppinen R, Sandholm J, Tanila H, Koistinaho M Multiple cellular and molecular mechanisms are involved in human Aβ clearance by transplanted adult astrocytes. Glia 2011, 59:1643-1657.
65. Iliff JJ, Wang M, Liao Y, et al. A paravascular pathway facilitates CSF flow through the brain parenchyma and the clearance of interstitial solutes, including amyloid β. Sci Transl Med 2012, 4:147ra111.
66. Patel NS, Paris D, Mathura V, Quadros AN, Crawford FC, Mullan MJ Inflammatory cytokine levels correlate with amyloid load in transgenic mouse models of Alzheimer's disease. J Neuroinflammation 2005, 2:9.
67. Lue LF, Rydel R, Brigham EF, et al. Inflammatory repertoire of Alzheimer's disease and nondemented elderly microglia in vitro. Glia 2001, 35:72-79.
68. Laske C, Stransky E, Hoffmann N, et al. Macrophage colony-stimulating factor (M-CSF) in plasma and CSF of patients with mild cognitive impairment and Alzheimer's disease. Curr Alzheimer Res 2010, 7:409-414.
69. Heneka MT, Kummer MP, Latz E, et al. Innate immune activation in neurodegenerative disease. Nat Rev Immunol 2014, 14:463-477.
70. Heneka MT, Kummer MP, Stutz A, et al. NLRP3 is activated in Alzheimer's disease and contributes to pathology in APP/PS1 mice. Nature 2013, 493:674-678.
71. Akama KT, Van Eldik LJ β-amyloid stimulation of inducible nitric-oxide synthase in astrocytes is interleukin-1β- and tumor necrosis factor-α (TNFα)-dependent, and involves a TNFα receptor-associated factor- and NFκB-inducing kinase-dependent signaling mechanism. J Biol Chem 2000, 275:7918-7924.
72. Mrak RE, Sheng JG, Griffin WS Glial cytokines in Alzheimer's disease: review and pathogenic implications. Hum Pathol 1995, 26:816-823.
73. Vom Berg J, Prokop S, Miller KR, et al. Inhibition of IL-12/IL-23 signaling reduces Alzheimer's disease-like pathology and cognitive decline. Nat Med 2012, 18:1812-1819.
74. Tan M-S, Yu J-T, Jiang T, Zhu X-C, Guan H-S, Tan L IL12/23 p40 inhibition ameliorates Alzheimer's disease-associated neuropathology and spatial memory in SAMP8 mice. J Alzheimers Dis 2014, 38:633-646.
75. Rentzos M, Paraskevas GP, Kapaki E, et al. Interleukin-12 is reduced in cerebrospinal fluid of patients with Alzheimer's disease and frontotemporal dementia. J Neurol Sci 2006, 249:110-114.
76. Tarkowski E, Andreasen N, Tarkowski A, Blennow K Intrathecal inflammation precedes development of Alzheimer's disease. J Neurol Neurosurg Psychiatry 2003, 74:1200-1205.
77. Meda L, Cassatella MA, Szendrei GI, et al. Activation of microglial cells by β-amyloid protein and interferon- γ. Nature 1995, 374:647-650.
78. Tan J, Town T, Paris D, et al. Microglial activation resulting from CD40-CD40L interaction after beta-amyloid stimulation. Science 1999, 286:2352-2355.
79. Tan J, Town T, Crawford F, et al. Role of CD40 ligand in amyloidosis in transgenic Alzheimer's mice. Nat Neurosci 2002, 5:1288-1293.
80. Jin J-J, Kim H-D, Maxwell JA, Li L, Fukuchi K Toll-like receptor 4-dependent upregulation of cytokines in a transgenic mouse model of Alzheimer's disease. J Neuroinflammation 2008, 5:23.
81. Shaftel SS, Carlson TJ, Olschowka JA, Kyrkanides S, Matousek SB, O'Banion MK Chronic interleukin-1β expression in mouse brain leads to leukocyte infiltration and neutrophil-independent blood brain barrier permeability without overt neurodegeneration. J Neurosci 2007, 27:9301-9309.
82. Ghosh S, Wu MD, Shaftel SS, et al. Sustained interleukin-1β overexpression exacerbates tau pathology despite reduced amyloid burden in an Alzheimer's mouse model. J Neurosci 2013, 33:5053-5064.
83. Chakrabarty P, Ceballos-Diaz C, Beccard A, et al. IFN-gamma promotes complement expression and attenuates amyloid plaque deposition in amyloid beta precursor protein transgenic mice. J Immunol 2010, 184:5333-5343.
84. Chakrabarty P, Jansen-West K, Beccard A, et al. Massive gliosis induced by interleukin-6 suppresses Aβ deposition in vivo: evidence against inflammation as a driving force for amyloid deposition. FASEB J 2010, 24:548-559.
85. Chakrabarty P, Herring A, Ceballos-Diaz C, Das P, Golde TE Hippocampal expression of murine TNFα results in attenuation of amyloid deposition in vivo. Mol Neurodegener 2011, 6:16.
86. Chakrabarty P, Tianbai L, Herring A, Ceballos-Diaz C, Das P, Golde TE Hippocampal expression of murine IL-4 results in exacerbation of amyloid deposition. Mol Neurodegener 2012, 7:36.
87. Savarin-Vuaillat C, Ransohoff RM Chemokines and chemokine receptors in neurological disease: raise, retain, or reduce?. Neurotherapeutics 2007, 4:590-601.
88. Xia MQ, Qin SX, Wu LJ, Mackay CR, Hyman BT Immunohistochemical study of the beta-chemokine receptors CCR3 and CCR5 and their ligands in normal and Alzheimer's disease brains. Am J Pathol 1998, 153:31-37.
89. Ishizuka K, Kimura T, Igata-yi R, Katsuragi S, Takamatsu J, Miyakawa T Identification of monocyte chemoattractant protein-1 in senile plaques and reactive microglia of Alzheimer's disease. Psychiatry Clin Neurosci 1997, 51:135-138.
90. Smits HA, Rijsmus A, van Loon JH, et al. Amyloid-beta-induced chemokine production in primary human macrophages and astrocytes. J Neuroimmunol 2002, 127:160-168.
91. Lue LF, Walker DG, Rogers J Modeling microglial activation in Alzheimer's disease with human postmortem microglial cultures. Neurobiol Aging 2001, 22:945-956.
92. Fuhrmann M, Bittner T, Jung CKE, et al. Microglial Cx3cr1 knockout prevents neuron loss in a mouse model of Alzheimer's disease. Nat Neurosci 2010, 13:411-413.
93. Lee S, Varvel NH, Konerth ME, et al. CX3CR1 deficiency alters microglial activation and reduces beta-amyloid deposition in two Alzheimer's disease mouse models. Am J Pathol 2010, 177:2549-2562.
94. Cho S-H, Sun B, Zhou Y, et al. CX3CR1 protein signaling modulates microglial activation and protects against plaque-independent cognitive deficits in a mouse model of Alzheimer disease. J Biol Chem 2011, 286:32713-32722.
95. Lee YK, Kwak DH, Oh KW, et al. CCR5 deficiency induces astrocyte activation, Aβ deposit and impaired memory function. Neurobiol Learn Mem 2009, 92:356-363.
96. Kiyota T, Yamamoto M, Xiong H, et al. CCL2 accelerates microglia-mediated Aβ oligomer formation and progression of neurocognitive dysfunction. PLoS One 2009, 4:e6197.
97. Semple BD, Frugier T, Morganti-Kossmann MC CCL2 modulates cytokine production in cultured mouse astrocytes. J Neuroinflammation 2010, 7:67.
98. Schroder K, Tschopp J The inflammasomes. Cell 2010, 140:821-832.
99. van de Veerdonk FL, Netea MG, Dinarello CA, Joosten LAB Inflammasome activation and IL-1β and IL-18 processing during infection. Trends Immunol 2011, 32:110-116.
100. Halle A, Hornung V, Petzold GC, et al. The NALP3 inflammasome is involved in the innate immune response to amyloid-β. Nat Immunol 2008, 9:857-865.
101. Fricker M, Vilalta A, Tolkovsky AM, Brown GC Caspase inhibitors protect neurons by enabling selective necroptosis of inflamed microglia. J Biol Chem 2013, 288:9145-9152.
102. Burguillos MA, Deierborg T, Kavanagh E, et al. Caspase signalling controls microglia activation and neurotoxicity. Nature 2011, 472:319-324.
103. Rohn TT, Kokoulina P, Eaton CR, Poon WW Caspase activation in transgenic mice with Alzheimer-like pathology: results from a pilot study utilizing the caspase inhibitor, Q-VD-OPh. Int J Clin Exp Med 2009, 2:300-308.
104. Biscaro B, Lindvall O, Tesco G, Ekdahl CT, Nitsch RM Inhibition of microglial activation protects hippocampal neurogenesis and improves cognitive deficits in a transgenic mouse model for Alzheimer's disease. Neurodegener Dis 2012, 9:187-198.
105. Choi S-H, Aid S, Caracciolo L, et al. Cyclooxygenase-1 inhibition reduces amyloid pathology and improves memory deficits in a mouse model of Alzheimer's disease. J Neurochem 2013, 124:59-68.
106. Montine TJ, Sidell KR, Crews BC, et al. Elevated CSF prostaglandin E2 levels in patients with probable AD. Neurology 1999, 53:1495-1498.
107. Slawik H, Volk B, Fiebich B, Hüll M Microglial expression of prostaglandin EP3 receptor in excitotoxic lesions in the rat striatum. Neurochem Int 2004, 45:653-660.
108. Shie F-S, Montine KS, Breyer RM, Montine TJ Microglial EP2 as a new target to increase amyloid beta phagocytosis and decrease amyloid beta-induced damage to neurons. Brain Pathol 2005, 15:134-138.
109. Liang X, Wang Q, Hand T, et al. Deletion of the prostaglandin E2 EP2 receptor reduces oxidative damage and amyloid burden in a model of Alzheimer's disease. J Neurosci 2005, 25:10180-10187.
110. Shi J, Wang Q, Johansson JU, et al. Inflammatory prostaglandin E2 signaling in a mouse model of Alzheimer disease. Ann Neurol 2012, 72:788-798.
111. Xiang Z, Ho L, Yemul S, et al. Cyclooxygenase-2 promotes amyloid plaque deposition in a mouse model of Alzheimer's disease neuropathology. Gene Expr 2002, 10:271-278.
112. Woodling NS, Wang Q, Priyam PG, et al. Suppression of Alzheimer-associated inflammation by microglial prostaglandin-E2 EP4 receptor signaling. J Neurosci 2014, 34:5882-5894.
113. Bazan NG, Molina MF, Gordon WC Docosahexaenoic acid signalolipidomics in nutrition: significance in aging, neuroinflammation, macular degeneration, Alzheimer's, and other neurodegenerative diseases. Annu Rev Nutr 2011, 31:321-351.
114. Lukiw WJ, Cui J-G, Marcheselli VL, et al. A role for docosahexaenoic acid-derived neuroprotectin D1 in neural cell survival and Alzheimer disease. J Clin Invest 2005, 115:2774-2783.
115. Zhao Y, Calon F, Julien C, et al. Docosahexaenoic acid-derived neuroprotectin D1 induces neuronal survival via secretase- and PPARγ-mediated mechanisms in Alzheimer's disease models. PLoS One 2011, 6:e15816.
116. Veerhuis R, Nielsen HM, Tenner AJ Complement in the brain. Mol Immunol 2011, 48:1592-1603.
117. Strohmeyer R, Ramirez M, Cole GJ, Mueller K, Rogers J Association of factor H of the alternative pathway of complement with agrin and complement receptor 3 in the Alzheimer's disease brain. J Neuroimmunol 2002, 131:135-146.
118. Lambert J-C, Heath S, Even G, et al. Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease. Nat Genet 2009, 41:1094-1099. the European Alzheimer's Disease Initiative Investigators.
119. Harold D, Abraham R, Hollingworth P, et al. Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease. Nat Genet 2009, 41:1088-1093.
120. Vodovotz Y, Lucia MS, Flanders KC, et al. Inducible nitric oxide synthase in tangle-bearing neurons of patients with Alzheimer's disease. J Exp Med 1996, 184:1425-1433.
121. Nathan C, Calingasan N, Nezezon J, et al. Protection from Alzheimer's-like disease in the mouse by genetic ablation of inducible nitric oxide synthase. J Exp Med 2005, 202:1163-1169.
122. Jekabsone A, Mander PK, Tickler A, Sharpe M, Brown GC Fibrillar β-amyloid peptide Aβ1-40 activates microglial proliferation via stimulating TNF-α release and H2O2 derived from NADPH oxidase: a cell culture study. J Neuroinflammation 2006, 3:24.
123. Choi S-H, Aid S, Kim H-W, Jackson SH, Bosetti F Inhibition of NADPH oxidase promotes alternative and anti-inflammatory microglial activation during neuroinflammation. J Neurochem 2012, 120:292-301.
124. Mander P, Brown GC Activation of microglial NADPH oxidase is synergistic with glial iNOS expression in inducing neuronal death: a dual-key mechanism of inflammatory neurodegeneration. J Neuroinflammation 2005, 2:20.
125. Butterfield DA, Reed TT, Perluigi M, et al. Elevated levels of 3-nitrotyrosine in brain from subjects with amnestic mild cognitive impairment: implications for the role of nitration in the progression of Alzheimer's disease. Brain Res 2007, 1148:243-248.
126. Kummer MP, Hermes M, Delekarte A, et al. Nitration of tyrosine 10 critically enhances amyloid β aggregation and plaque formation. Neuron 2011, 71:833-844.
127. Thiabaud G, Pizzocaro S, Garcia-Serres R, Latour J-M, Monzani E, Casella L Heme binding induces dimerization and nitration of truncated β-amyloid peptide Aβ16 under oxidative stress. Angew Chem Int Ed Engl 2013, 52:8041-8044.
128. Cho D-H, Nakamura T, Fang J, et al. S-nitrosylation of Drp1 mediates β-amyloid-related mitochondrial fission and neuronal injury. Science 2009, 324:102-105.
129. Iadecola C Neurovascular regulation in the normal brain and in Alzheimer's disease. Nat Rev Neurosci 2004, 5:347-360.
130. Shin HK, Jones PB, Garcia-Alloza M, et al. Age-dependent cerebrovascular dysfunction in a transgenic mouse model of cerebral amyloid angiopathy. Brain 2007, 130:2310-2319.
131. Petzold GC, Murthy VN Role of astrocytes in neurovascular coupling. Neuron 2011, 71:782-797.
132. Jarre A, Gowert NS, Donner L, et al. Pre-activated blood platelets and a pro-thrombotic phenotype in APP23 mice modeling Alzheimer's disease. Cell Signal 2014, 26:2040-2050.
133. Deane R, Du Yan S, Submamaryan RK, et al. RAGE mediates amyloid-β peptide transport across the blood-brain barrier and accumulation in brain. Nat Med 2003, 9:907-913.
134. Zlokovic BV Neurovascular pathways to neurodegeneration in Alzheimer's disease and other disorders. Nat Rev Neurosci 2011, 12:723-738.
135. Hart BL Biological basis of the behavior of sick animals. Neurosci Biobehav Rev 1988, 12:123-137.
136. Yang H, Ochani M, Li J, et al. Reversing established sepsis with antagonists of endogenous high-mobility group box 1. Proc Natl Acad Sci USA 2004, 101:296-301.
137. Rivest S Regulation of innate immune responses in the brain. Nat Rev Immunol 2009, 9:429-439.
138. Undén A-L, Andréasson A, Elofsson S, et al. Inflammatory cytokines, behaviour and age as determinants of self-rated health in women. Clin Sci (Lond) 2007, 112:363-373.
139. Maitra U, Deng H, Glaros T, et al. Molecular mechanisms responsible for the selective and low-grade induction of proinflammatory mediators in murine macrophages by lipopolysaccharide. J Immunol 2012, 189:1014-1023.
140. Pace JL, Russell SW, Torres BA, Johnson HM, Gray PW Recombinant mouse gamma interferon induces the priming step in macrophage activation for tumor cell killing. J Immunol 1983, 130:2011-2013.
141. Godbout JP, Johnson RW Age and neuroinflammation: a lifetime of psychoneuroimmune consequences. Immunol Allergy Clin North Am 2009, 29:321-337.
142. Cunningham C, Wilcockson DC, Campion S, Lunnon K, Perry VH Central and systemic endotoxin challenges exacerbate the local inflammatory response and increase neuronal death during chronic neurodegeneration. J Neurosci 2005, 25:9275-9284.
143. Cunningham C, Campion S, Lunnon K, et al. Systemic inflammation induces acute behavioral and cognitive changes and accelerates neurodegenerative disease. Biol Psychiatry 2009, 65:304-312.
144. Field R, Campion S, Warren C, Murray C, Cunningham C Systemic challenge with the TLR3 agonist poly I:C induces amplified IFNalpha/beta and IL-1beta responses in the diseased brain and exacerbates chronic neurodegeneration. Brain Behav Immun 2010, 24:996-1007.
145. Kyrkanides S, Tallents RH, Miller JN, et al. Osteoarthritis accelerates and exacerbates Alzheimer's disease pathology in mice. J Neuroinflammation 2011, 8:112.
146. Holmes C, Cunningham C, Zotova E, et al. Systemic inflammation and disease progression in Alzheimer disease. Neurology 2009, 73:768-774.
147. Holmes C, Cunningham C, Zotova E, Culliford D, Perry VH Proinflammatory cytokines, sickness behavior, and Alzheimer disease. Neurology 2011, 77:212-218.
148. Almond MH, Edwards MR, Barclay WS, Johnston SL Obesity and susceptibility to severe outcomes following respiratory viral infection. Thorax 2013, 68:684-686.
149. Chidiac C Pneumococcal infections and adult with risk factors. Med Mal Infect 2012, 42:517-524.
150. Bastard J-P, Maachi M, Lagathu C, et al. Recent advances in the relationship between obesity, inflammation, and insulin resistance. Eur Cytokine Netw 2006, 17:4-12.
151. Whitmer RA, Gustafson DR, Barrett-Connor E, Haan MN, Gunderson EP, Yaffe K Central obesity and increased risk of dementia more than three decades later. Neurology 2008, 71:1057-1064.
152. Brown BM, Peiffer JJ, Martins RN Multiple effects of physical activity on molecular and cognitive signs of brain aging: can exercise slow neurodegeneration and delay Alzheimer's disease?. Mol Psychiatry 2013, 18:864-874.
153. Takeda S, Sato N, Uchio-Yamada K, et al. Diabetes-accelerated memory dysfunction via cerebrovascular inflammation and Aβ deposition in an Alzheimer mouse model with diabetes. Proc Natl Acad Sci USA 2010, 107:7036-7041.
154. Le Chatelier E, Nielsen T, Qin J, et al. Richness of human gut microbiome correlates with metabolic markers. Nature 2013, 500:541-546. the MetaHIT consortium.
155. Sivanandam TM, Thakur MK Traumatic brain injury: a risk factor for Alzheimer's disease. Neurosci Biobehav Rev 2012, 36:1376-1381.
156. Brody DL, Holtzman DM Morris water maze search strategy analysis in PDAPP mice before and after experimental traumatic brain injury. Exp Neurol 2006, 197:330-340.
157. Tajiri N, Kellogg SL, Shimizu T, Arendash GW, Borlongan CV Traumatic brain injury precipitates cognitive impairment and extracellular Aβ aggregation in Alzheimer's disease transgenic mice. PLoS One 2013, 8:e78851.
158. Koshinaga M, Katayama Y, Fukushima M, Oshima H, Suma T, Takahata T Rapid and widespread microglial activation induced by traumatic brain injury in rat brain slices. J Neurotrauma 2000, 17:185-192.
159. Ramlackhansingh AF, Brooks DJ, Greenwood RJ, et al. Inflammation after trauma: microglial activation and traumatic brain injury. Ann Neurol 2011, 70:374-383.
160. Sastre M, Dewachter I, Landreth GE, et al. Nonsteroidal anti-inflammatory drugs and peroxisome proliferator-activated receptor-gamma agonists modulate immunostimulated processing of amyloid precursor protein through regulation of beta-secretase. J Neurosci 2003, 23:9796-9804.
161. Corrigan F, Pham CLL, Vink R, et al. The neuroprotective domains of the amyloid precursor protein, in traumatic brain injury, are located in the two growth factor domains. Brain Res 2011, 1378:137-143.
162. O'Donnell J, Zeppenfeld D, McConnell E, Pena S, Nedergaard M Norepinephrine: a neuromodulator that boosts the function of multiple cell types to optimize CNS performance. Neurochem Res 2012, 37:2496-2512.
163. Marien MR, Colpaert FC, Rosenquist AC Noradrenergic mechanisms in neurodegenerative diseases: a theory. Brain Res Brain Res Rev 2004, 45:38-78.
164. Zarow C, Lyness SA, Mortimer JA, Chui HC Neuronal loss is greater in the locus coeruleus than nucleus basalis and substantia nigra in Alzheimer and Parkinson diseases. Arch Neurol 2003, 60:337-341.
165. Kalinin S, Gavrilyuk V, Polak PE, et al. Noradrenaline deficiency in brain increases beta-amyloid plaque burden in an animal model of Alzheimer's disease. Neurobiol Aging 2007, 28:1206-1214.
166. Heneka MT, Ramanathan M, Jacobs AH, et al. Locus ceruleus degeneration promotes Alzheimer pathogenesis in amyloid precursor protein 23 transgenic mice. J Neurosci 2006, 26:1343-1354.
167. O'Sullivan JB, Ryan KM, Harkin A, Connor TJ Noradrenaline reuptake inhibitors inhibit expression of chemokines IP-10 and RANTES and cell adhesion molecules VCAM-1 and ICAM-1 in the CNS following a systemic inflammatory challenge. J Neuroimmunol 2010, 220:34-42.
168. Kalinin S, Polak PE, Lin SX, Sakharkar AJ, Pandey SC, Feinstein DL The noradrenaline precursor L-DOPS reduces pathology in a mouse model of Alzheimer's disease. Neurobiol Aging 2012, 33:1651-1663.
169. Bolmont T, Haiss F, Eicke D, et al. Dynamics of the microglial/amyloid interaction indicate a role in plaque maintenance. J Neurosci 2008, 28:4283-4292.
170. Meyer-Luehmann M, Coomaraswamy J, Bolmont T, et al. Exogenous induction of cerebral beta-amyloidogenesis is governed by agent and host. Science 2006, 313:1781-1784.
171. Kim JV, Dustin ML Innate response to focal necrotic injury inside the blood-brain barrier. J Immunol 2006, 177:5269-5277.
172. Perry VH, Nicoll JAR, Holmes C Microglia in neurodegenerative disease. Nat Rev Neurol 2010, 6:193-201.
173. Rupprecht R, Papadopoulos V, Rammes G, et al. Translocator protein (18 kDa) (TSPO) as a therapeutic target for neurological and psychiatric disorders. Nat Rev Drug Discov 2010, 9:971-988.
174. Jacobs AH, Tavitian B Noninvasive molecular imaging of neuroinflammation. J Cereb Blood Flow Metab 2012, 32:1393-1415. the INMiND consortium.
175. Venneti S, Lopresti BJ, Wang G, et al. PK11195 labels activated microglia in Alzheimer's disease and in vivo in a mouse model using PET. Neurobiol Aging 2009, 30:1217-1226.
176. Roberts JC, Friel SL, Roman S, et al. Autoradiographical imaging of PPARgamma agonist effects on PBR/TSPO binding in TASTPM mice. Exp Neurol 2009, 216:459-470.
177. Rapic S, Backes H, Viel T, et al. Imaging microglial activation and glucose consumption in a mouse model of Alzheimer's disease. Neurobiol Aging 2013, 34:351-354.
178. Heneka MT, Reyes-Irisarri E, Hüll M, Kummer MP Impact and Therapeutic Potential of PPARs in Alzheimer's Disease. Curr Neuropharmacol 2011, 9:643-650.
179. Chauveau F, Boutin H, Van Camp N, et al. In vivo imaging of neuroinflammation in the rodent brain with [11C]SSR180575, a novel indoleacetamide radioligand of the translocator protein (18 kDa). Eur J Nucl Med Mol Imaging 2011, 38:509-514.
180. Chauveau F, Van Camp N, Dollé F, et al. Comparative evaluation of the translocator protein radioligands 11C-DPA-713, 18F-DPA-714, and 11C-PK11195 in a rat model of acute neuroinflammation. J Nucl Med 2009, 50:468-476.
181. 11C]PK11195 positron emission tomography study. Neurobiol Aging 2013, 34:128-136.
182. 11C]DAA1106. Psychiatry Res 2012, 203:67-74.
183. Edison P, Archer H, Hinz R, et al. Relationship between the distribution of microglial activation and amyloid deposition in Alzheimer's disease: An 11C-PK11195 and 11C-PIB PET study. J Neurol Neurosurg Psychiatry 2007, 78:219.
184. Yokokura M, Mori N, Yagi S, et al. In vivo changes in microglial activation and amyloid deposits in brain regions with hypometabolism in Alzheimer's disease. Eur J Nucl Med Mol Imaging 2011, 38:343-351.
185. Edison P, Archer HA, Hinz R, et al. Amyloid, hypometabolism, and cognition in Alzheimer disease: an [11C]PIB and [18F]FDG PET study. Neurology 2007, 68:501-508.
186. Kreisl WC, Lyoo CH, McGwier M, et al. In vivo radioligand binding to translocator protein correlates with severity of Alzheimer's disease. Brain 2013, 136:2228-2238. the Biomarkers Consortium PET Radioligand Project Team.
187. Okello A, Edison P, Archer HA, et al. Microglial activation and amyloid deposition in mild cognitive impairment: a PET study. Neurology 2009, 72:56-62.
188. Shi H, Belbin O, Medway C, et al. Genetic variants influencing human aging from late-onset Alzheimer's disease (LOAD) genome-wide association studies (GWAS). Neurobiol Aging 2012, 33:1849.e5. 1849.18.
189. Brosseron F, Krauthausen M, Kummer M, Heneka MT Body fluid cytokine levels in mild cognitive impairment and Alzheimer's disease: a comparative overview. Mol Neurobiol 2014, 50:534-544.
190. Galimberti D, Fenoglio C, Scarpini E Inflammation in neurodegenerative disorders: friend or foe?. Curr Aging Sci 2008, 1:30-41.
191. Czirr E, Wyss-Coray T The immunology of neurodegeneration. J Clin Invest 2012, 122:1156-1163.
192. Ruckh JM, Zhao J-W, Shadrach JL, et al. Rejuvenation of regeneration in the aging central nervous system. Cell Stem Cell 2012, 10:96-103.
193. Villeda S, Wyss-Coray T Microglia-a wrench in the running wheel?. Neuron 2008, 59:527-529.
194. Lista S, Faltraco F, Hampel H Biological and methodical challenges of blood-based proteomics in the field of neurological research. Prog Neurobiol 2013, 101-102:18-34.
195. Green MJ, Matheson SL, Shepherd A, Weickert CS, Carr VJ Brain-derived neurotrophic factor levels in schizophrenia: a systematic review with meta-analysis. Mol Psychiatry 2011, 16:960-972.
196. Kurita M, Nishino S, Kato M, Numata Y, Sato T Plasma brain-derived neurotrophic factor levels predict the clinical outcome of depression treatment in a naturalistic study. PLoS One 2012, 7:e39212.
197. Lee B-H, Kim H, Park S-H, Kim Y-K Decreased plasma BDNF level in depressive patients. J Affect Disord 2007, 101:239-244.
198. Martinotti G, Di Iorio G, Marini S, Ricci V, De Berardis D, Di Giannantonio M Nerve growth factor and brain-derived neurotrophic factor concentrations in schizophrenia: a review. J Biol Regul Homeost Agents 2012, 26:347-356.
199. Hu WT, Holtzman DM, Fagan AM, et al. Plasma multianalyte profiling in mild cognitive impairment and Alzheimer disease. Neurology 2012, 79:897-905. the Alzheimer's Disease Neuroimaging Initiative.
200. Ray S, Britschgi M, Herbert C, et al. Classification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins. Nat Med 2007, 13:1359-1362.
201. Soares HD, Potter WZ, Pickering E, et al. Plasma biomarkers associated with the apolipoprotein E genotype and Alzheimer disease. Arch Neurol 2012, 69:1310-1317. the Biomarkers Consortium Alzheimer's Disease Plasma Proteomics Project.
202. Britschgi M, Rufibach K, Huang SLB, et al. Modeling of pathological traits in Alzheimer's disease based on systemic extracellular signaling proteome. Mol Cell Proteomics 2011, 10. M111.008862.
203. Johnstone D, Milward EA, Berretta R, Moscato P Multivariate protein signatures of pre-clinical Alzheimer's disease in the Alzheimer's disease neuroimaging initiative (ADNI) plasma proteome dataset. PLoS One 2012, 7:e34341. the Alzheimer's Disease Neuroimaging Initiative.
204. Rogers J, Kirby LC, Hempelman SR, et al. Clinical trial of indomethacin in Alzheimer's disease. Neurology 1993, 43:1609-1611.
205. de Jong D, Jansen R, Hoefnagels W, et al. No effect of one-year treatment with indomethacin on Alzheimer's disease progression: a randomized controlled trial. PLoS One 2008, 3:e1475.
206. Aisen PS, Davis KL, Berg JD, et al. A randomized controlled trial of prednisone in Alzheimer's disease. Alzheimer's Disease Cooperative Study. Neurology 2000, 54:588-593.
207. Aisen PS, Schafer KA, Grundman M, et al. Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial. JAMA 2003, 289:2819-2826. the Alzheimer's Disease Cooperative Study.
208. Aisen PS, Schmeidler J, Pasinetti GM Randomized pilot study of nimesulide treatment in Alzheimer's disease. Neurology 2002, 58:1050-1054.
209. Reines SA, Block GA, Morris JC, et al. Rofecoxib: no effect on Alzheimer's disease in a 1-year, randomized, blinded, controlled study. Neurology 2004, 62:66-71. the Rofecoxib Protocol 091 Study Group.
210. Thal LJ, Ferris SH, Kirby L, et al. A randomized, double-blind, study of rofecoxib in patients with mild cognitive impairment. Neuropsychopharmacology 2005, 30:1204-1215. the Rofecoxib Protocol 078 study group.
211. Van Gool WA, Weinstein HC, Scheltens P, Walstra GJ Effect of hydroxychloroquine on progression of dementia in early Alzheimer's disease: an 18-month randomised, double-blind, placebo-controlled study. Lancet 2001, 358:455-460.
212. Martin BK, Szekely C, Brandt J, et al. Cognitive function over time in the Alzheimer's Disease Anti-inflammatory Prevention Trial (ADAPT): results of a randomized, controlled trial of naproxen and celecoxib. Arch Neurol 2008, 65:896-905. the ADAPT Research Group.
213. Lyketsos CG, Breitner JC, Green RC, et al. Naproxen and celecoxib do not prevent AD in early results from a randomized controlled trial. Neurology 2007, 68:1800-1808. the ADAPT Research Group.
214. Simons M, Schwärzler F, Lütjohann D, et al. Treatment with simvastatin in normocholesterolemic patients with Alzheimer's disease: a 26-week randomized, placebo-controlled, double-blind trial. Ann Neurol 2002, 52:346-350.
215. Sparks DL, Sabbagh MN, Connor DJ, et al. Atorvastatin for the treatment of mild to moderate Alzheimer disease: preliminary results. Arch Neurol 2005, 62:753-757.
216. Feldman HH, Doody RS, Kivipelto M, et al. Randomized controlled trial of atorvastatin in mild to moderate Alzheimer disease: LEADe. Neurology 2010, 74:956-964. the LEADe Investigators.
217. Harrington C, Sawchak S, Chiang C, et al. Rosiglitazone does not improve cognition or global function when used as adjunctive therapy to AChE inhibitors in mild-to-moderate Alzheimer's disease: two phase 3 studies. Curr Alzheimer Res 2011, 8:592-606.
218. Breitner JC, Baker LD, Montine TJ, et al. Extended results of the Alzheimer's disease anti-inflammatory prevention trial. Alzheimers Dement 2011, 7:402-411. the ADAPT Research Group.
219. Results of a follow-up study to the randomized Alzheimer's Disease Anti-inflammatory Prevention Trial (ADAPT). Alzheimers Dement 2013, 9:714-723. Alzheimer's Disease Anti-inflammatory Prevention Trial Research Group.
220. Cribbs DH, Berchtold NC, Perreau V, et al. Extensive innate immune gene activation accompanies brain aging, increasing vulnerability to cognitive decline and neurodegeneration: a microarray study. J Neuroinflammation 2012, 9:179.
221. Shi J, Johansson J, Woodling NS, Wang Q, Montine TJ, Andreasson K The prostaglandin E2 E-prostanoid 4 receptor exerts anti-inflammatory effects in brain innate immunity. J Immunol 2010, 184:7207-7218.
222. Tang EHC, Libby P, Vanhoutte PM, Xu A Anti-inflammation therapy by activation of prostaglandin EP4 receptor in cardiovascular and other inflammatory diseases. J Cardiovasc Pharmacol 2012, 59:116-123.
223. Brenneis C, Coste O, Altenrath K, et al. Anti-inflammatory role of microsomal prostaglandin E synthase-1 in a model of neuroinflammation. J Biol Chem 2011, 286:2331-2342.
224. Bentham P, Gray R, Sellwood E, Hills R, Crome P, Raftery J Aspirin in Alzheimer's disease (AD2000): a randomised open-label trial. Lancet Neurol 2008, 7:41-49. the AD2000 Collaborative Group.
225. Wilcock DM, Zhao Q, Morgan D, et al. Diverse inflammatory responses in transgenic mouse models of Alzheimer's disease and the effect of immunotherapy on these responses. ASN Neuro 2011, 3:249-258.
226. Jimenez S, Baglietto-Vargas D, Caballero C, et al. Inflammatory response in the hippocampus of PS1M146L/APP751SL mouse model of Alzheimer's disease: age-dependent switch in the microglial phenotype from alternative to classic. J Neurosci 2008, 28:11650-11661.
227. Morgan D, Gordon MN, Tan J, Wilcock D, Rojiani AM Dynamic complexity of the microglial activation response in transgenic models of amyloid deposition: implications for Alzheimer therapeutics. J Neuropathol Exp Neurol 2005, 64:743-753.
228. Zotova E, Bharambe V, Cheaveau M, et al. Inflammatory components in human Alzheimer's disease and after active amyloid-β42 immunization. Brain 2013, 136:2677-2696.
229. Boche D, Zotova E, Weller RO, et al. Consequence of Aβ immunization on the vasculature of human Alzheimer's disease brain. Brain 2008, 131:3299-3310.
230. Wilcock DM, Rojiani A, Rosenthal A, et al. Passive immunotherapy against Aβ in aged APP-transgenic mice reverses cognitive deficits and depletes parenchymal amyloid deposits in spite of increased vascular amyloid and microhemorrhage. J Neuroinflammation 2004, 1:24.
231. Sperling R, Salloway S, Brooks DJ, et al. Amyloid-related imaging abnormalities in patients with Alzheimer's disease treated with bapineuzumab: a retrospective analysis. Lancet Neurol 2012, 11:241-249.
232. Wilcock DM, Alamed J, Gottschall PE, et al. Deglycosylated anti-amyloid-β antibodies eliminate cognitive deficits and reduce parenchymal amyloid with minimal vascular consequences in aged amyloid precursor protein transgenic mice. J Neurosci 2006, 26:5340-5346.